Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEVE UCCD LTE long-term extension study of TEV-48574 in ulcerative colitis and Crohn’s disease
2024-515027-11-00Phase 2Authorised
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of duvakitug in autoimmune colitis and Crohn's disease, sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Clinical remission in ulcerative colitis at week 44 and Endoscopic response in Crohn’s disease at week 44. Planned start Sep 2024; status: authorised.
02
Drugs
duvakitug
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2024-515027-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515027-11-00.